[Special Stock] Onconic Therapeutics Confirms Up to 99.3% Tumor Reduction in Gastric Cancer

Onconic Therapeutics showed strong gains in early trading. The company's gastric cancer treatment candidate 'Nesuparib' demonstrated superior anticancer efficacy compared to existing products, boosting investor sentiment.

As of 9:06 a.m. on April 30, shares of Onconic Therapeutics were trading at 24,800 won, up 17.26% (3,650 won) from the previous day.

On this day, Onconic Therapeutics announced that it had presented preclinical research results on the next-generation dual-mechanism anticancer candidate Nesuparib for gastric cancer indications at the '2025 American Association for Cancer Research (AACR 2025)' held in Chicago, United States.

Nesuparib is a novel drug candidate that simultaneously inhibits PARP, which is involved in the repair of DNA (deoxyribonucleic acid) damage in cancer cells, and tankyrase (TNKS), which affects cancer growth and progression.

At the Chicago presentation, Onconic Therapeutics unveiled new results from animal model studies using patient-derived gastric cancer cells, confirming the anticancer efficacy of Nesuparib. When administered in combination with irinotecan, the standard treatment for gastric cancer, Nesuparib showed a 92.4% tumor reduction, demonstrating a significantly superior tumor reduction effect compared to existing drugs.

In another animal study using NCI-N87 gastric cancer cells, which are HER2 (human epidermal growth factor receptor 2)-positive, the group treated with Nesuparib alone showed a 74% tumor reduction compared to the untreated control group. When administered in combination with irinotecan, a 99.3% tumor reduction was observed compared to the untreated control group.

A representative from Onconic Therapeutics stated, "Nesuparib has reaffirmed its value as a next-generation synthetic lethality anticancer drug that simultaneously inhibits PARP and tankyrase," adding, "We will accelerate research and development with the goal of rapidly entering Phase 2 clinical trials."